Mazdutide (IBI362) Research Guide 2026: GLP-1/GCGR Dual Agonist Mechanism, Synthesis, and COA

Product Deep Dive | 2026-07-09 | 11 min read

A 2026 research guide to mazdutide (IBI362): GLP-1/GCGR dual agonism mechanism, amino acid sequence, synthesis challenges, analytical characterization, and COA specification for laboratory researchers.

What is mazdutide and why is it getting attention in 2026

Mazdutide, developed by Innovent Biologics (IBI362), is a GLP-1 and glucagon receptor (GCGR) dual agonist that entered Phase 3 trials in 2023 and has shown compelling Phase 2 data for obesity and type 2 diabetes. The dual agonism mechanism — targeting both GLP-1R and GCGR — produces greater weight loss than selective GLP-1 agonists by adding a glucagon-driven thermogenic component.

In Phase 2 trials, mazdutide at 9mg weekly produced approximately 12-15% body weight reduction at 24 weeks, comparable to tirzepatide (15mg) and ahead of semaglutide (2.4mg). The combination of efficacy and a potentially favorable safety profile has made it a priority compound for metabolic research programs.

GLP-1/GCGR dual agonism: mechanism and rationale

Two receptors, one peptide:

• **GLP-1 receptor (GLP-1R)** — drives satiety, slows gastric emptying, enhances insulin secretion, suppresses glucagon
• **Glucagon receptor (GCGR)** — drives hepatic glucose output, lipolysis, and energy expenditure via thermogenesis

Selective GLP-1 agonists (semaglutide, liraglutide) activate GLP-1R only. Dual agonists activate both receptors simultaneously. The glucagon component adds:

• Increased energy expenditure through thermogenesis
• Enhanced lipolysis
• Improved lipid metabolism
• Greater hepatic fat reduction

The challenge is balancing GCGR activation — too much produces hyperglycemia — which is why mazdutide is engineered with biased signaling that favors GLP-1R over GCGR.

Amino acid sequence and structural modifications

Mazdutide is a modified human GLP-1(7-36) amide analog. Key modifications:

• **Aib at position 2** — prevents DPP-4 degradation, extends half-life
• **Lys at position 20** — site for fatty diacid conjugation
• **C18 fatty diacid chain at Lys20** — albumin binding extends half-life to weekly dosing
• **Amidation at C-terminus** — maintains receptor potency

The sequence contains 39 amino acids with three non-natural modifications. Total molecular weight is approximately 4,982 Da (without the fatty diacid chain).

Synthesis challenges and production considerations

Three synthesis challenges define mazdutide production:

• **Non-natural amino acid incorporation** — Aib (aminoisobutyric acid) requires specialized reagents and extended coupling cycles
• **Fatty diacid conjugation** — site-specific conjugation at Lys20 requires controlled derivatization chemistry
• **Longer sequence** — 39 amino acids increases aggregation risk during cleavage and purification

SPPS is the primary synthetic route. Recombinant expression is not currently competitive due to the non-natural amino acid modifications.

Purification via RP-HPLC at high pH (typically pH 8-9) separates the target from deletion and truncation sequences. The fatty diacid conjugation step requires orthogonal protection-deprotection chemistry.

Analytical characterization: COA specification

A compliant COA for mazdutide research peptide includes:

| Test | Method | Acceptance Criterion | | --- | --- | --- | | Appearance | Visual | White to off-white lyophilized powder | | HPLC Purity | RP-HPLC, 220nm | ≥95% | | MS (ESI) | Mass spectrometry | ±0.5% of theoretical m/z | | Endotoxin | LAL kinetic chromogenic | <1.0 EU/mg | | Water content | KF titration | <3% | | Residual solvents | GC headspace | Within ICH Q3C limits | | Fatty acid content | HPLC-ELSD | 90-110% of label claim |

Counterfeit or truncated sequences are the most common quality risk. Verify MS data against the theoretical mass before accepting any mazdutide lot.

Research applications and peer-reviewed literature

Mazdutide research applications in 2025-2026 include:

• Obesity pharmacotherapy: Phase 3 SURMOUNT-IBI program (Innovent)
• Type 2 diabetes: Phase 2 DREAMS program showing HbA1c reduction of 1.5-2.0%
• Metabolic dysfunction-associated steatohepatitis (MASH): early-phase data showing hepatic fat reduction
• Cardiovascular risk reduction: ongoing CV outcomes trial

Key references:

• Ji et al., Lancet Diabetes Endocrinol 2024 — Phase 2 dose-finding study
• Wharton et al., N Engl J Med 2024 — mazdutide vs. placebo in obesity
• Innovent Biologics IBI362 development pipeline update, 2025

Stability and storage

Mazdutide is stable as a lyophilized powder:

• Short-term: 2-8°C for up to 4 weeks (for working stock)
• Long-term: -20°C or below, protected from light and moisture
• Container: sealed vial under nitrogen or vacuum

Reconstituted solution (in sterile water or PBS, pH 7.4) is stable for:

• 28 days at 2-8°C
• 72 hours at room temperature

Avoid repeated freeze-thaw cycles. Divide into single-use aliquots after reconstitution.

Sourcing considerations

Three sourcing risks for mazdutide:

• **Sequence integrity** — verify MS data against the theoretical mass; truncation at the C-terminus is common in low-quality lots
• **Fatty diacid substitution** — confirm substitution at Lys20 specifically; random conjugation produces a heterogeneous product
• **Purity claims** — accept ≥95% by HPLC with supporting chromatogram; single-point purity claims without chromatogram are unverifiable

ZePeptide supplies mazdutide for laboratory research with ≥95% HPLC purity, full COA (HPLC, MS, endotoxin, fatty acid content), and cold-chain packaging validated for international shipment.

ZePeptide content is for lawful laboratory and in-vitro research sourcing. Products are not supplied for human or veterinary use.